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Summary
We have studied the consequences ofintroducing human recombinant transforming growth factor
01 (hrTGF-i61) into synovial tissue of the rat, to begin to better understand the significance of
the fact that biologically active TGF-0 is found in human arthritic synovial effusions. Within
4-6 h after the intra-articular injection of 1 lAg ofhrTGF-f31 into rat kneejoints, extensive recruitment
of polymorphonuclear leukocytes (PMNs) was observed. Cytochemistry and high resolution
histological techniques were used to quantitate the influx of PMNs, which peaked 6 h post-
injection . In a Boyden chamber assay, hrTGF-/31 at 1-10 fg/ml elicited a chemotactic response
from PMNs greater in magnitude than that evoked by FMLP, establishing that TGF-01 is an
effective chemotactic agent for PMNs in vitro as well as in vivo. That PMNs may represent
an important source ofTGF-0 in inflammatory infiltrates was strongly suggested by a demonstration
that stored TGF-/31 was secreted during phorbol myristate acetate-stimulated degranulation in
vitro. Acid/ethanol extracts ofhuman PMNs assayed by ELISA contained an average of 355 ng
of TGF/ail per 109 cells potentially available for secretion during degranulation of PMNs.
[3H]Thymidine incorporation in vivo and autoradiography of tissue sections revealed that
widespread cell proliferation was triggered by TGF-01 injection . Synovial lining cells and cells
located deep within the subsynovial connective tissue were identified as sources of at least some
of the new cells that contribute to TGF-(31-induced hyperplasia . Our results demonstrate that
TGF-0 is capable of exerting pathogenic effects on synovial tissue and that PMNs may represent
a significant source of the TGF-0 present in synovial effusions .
S
ignificant levels of both active and latent transforming
growth factor (3 (TGF-/31)1 are found in the synovial
effusions associated with rheumatoid arthritis, osteoarthritis,
and gout (1-3) . TGF-01 mRNA is detectable in extracts of
diseased synovial tissues, and immunological evidence for its
presence in synovial tissues has been reported as well (4) . These
data, and many ofits effects on pertinent cell types, have im-
plicated TGF-/3 in the pathogenesis of these arthritides .
Specifically, TGF-,13 exerts dramatic effects on extracellular
matrix deposition by mesenchymal cells (5-8), induces chemo-
1 Abbreviation used in this paper . hrTGF-01, human recombinant trans-
forming growth factor ,81 .
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taxis of fibroblasts in vivo (9) and in vitro (10), promotes
angiogenesis (9, 11), exerts complex effects on chondrocytes
(12), and can recruit monocytes and modulate monocyte ac-
tivation (13-15) . However, TGF-/3 also exerts suppressive effects
on cells oftheimmune system that could have beneficial effects
on synovial pathogenesis (16-19) . In fact, its presence in sy-
novial effusions seems to explain a long recognized paradox :
that of a diminished responsiveness to T cell mitogens ex-
hibited by otherwise activated synovialT cells (2, 18, 20-22) .
To begin to identify and define synovial tissue responses
to TGF-#1 in vivo, we investigated the consequences of in-
jecting hfGF-01 into normal synovial tissue. Our results
demonstrate that through chemoattraction ofneutrophils and
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1121-1132other mechanisms, TGF-01 has a significant potential to exert
pathogenic effects in the synovium and surrounding tissues
that could contribute to development of thesynovial pannus
in arthritis.
Materials and Methods
Cytokines and Reagents.
￿
Recombinant humanTGF-01(hrTGF-
(31) and 'ZSI-TGF-0 were generously donated by Genentech, Inc.
(So. San Francisco, CA). Endotoxin levels in this preparation of
human recombinant TGF/01 were determined to be 1.84 x 10-3
endotoxin U/FAg by the limulusPolyphemus gelation assay. Purified
porcineTGF-/31 and a neutralizing antiserum against TGF-Owere
fromR + D Systems, Inc. (Minneapolis, MN). The preparations
of hrTGF-0l used throughout this study showed virtually iden-
tical competing activity andbinding parameters when compared
with purified porcine TGF-O in receptor competition assays on
AKR2B fibroblasts (23) . 'IIITGF-a (a gift of Genentech, Inc.)
was used in preliminary experiments ; in confirming experiments,
hrTGF-a1 was iodinated (24) and analyzed by receptor competi-
tion assay (23) to check its bioactivity, andby SDS-PAGE and auto-
radiography to confirm its purity . [3H]Thymidine (2.0 Ci/mmol)
was from Dupont/New England Nuclear (Wilmington, DE) .
FMLP was purchasedfrom SigmaChemical Co. (St. Louis, MO).
Experimental Animals.
￿
6-wk-old female Wistar Outbred rats
(175 g) obtained from Harlan Sprague Dawley (Indianapolis, IN)
were used formost intra-articular injection studies. C3H/OuJ mice,
used in thymidine labeling experiments, were 6-12 mo old when
used andwere obtained from TheJackson Laboratory (Bar Harbor,
ME). Animals were housed in the animalcare facilities at the Depart-
ment of Veterans Affairs Medical Center (Nashville, TN) and given
food and water ad libitum . After study, all animals were killed by
carbon dioxide narcosis.
Intm-articularInjection ofTCR0 andHistological Techniques.
￿
Rats
were anesthetized with amixture ofketamine/xylazine (80 hg/g
ketamine; 12 Ag/g xylazine) sufficient to keep the animalsuncon-
scious for 3-4h. Injections were performedwith 31-gauge needle
tubing attached to amechanical syringe driver (Hamilton Co., Reno,
NV). The knee joint was slightly flexed, and the needle was in-
serted through the infrapatellar fat pad into thejoint cavity. Either
1 ug of recombinant human TGF-S1 in 25 pl sterile saline, or 25
N.1 sterile saline alone as a control, was injected into the intra-articular
joint spaces . Three animalswere killed for each time point exam-
ined (2, 4, 6, 8, 12, 24, 48, and 72 h, 6 and 17 d post-injection),
andthe tissue was fixed and decalcified, embedded in paraffin, sec-
tioned, and examined for cellular infiltration, plasma exudation,
and synovial membrane thickening or "hyperplasid". In each case,
sagittal sections that included views ofthejoint space, the meniscal
cartilage, tibial and femoral cartilage surfaces, the infrapatellar fat
pad, and its lining (synovial membrane) were examined . In this
manner, cytokine-induced changes in the typically loose connec-
tive tissue ofthe fat padwere not confused with the normallymore
fibrous and cellular perichondral regions of the synovium .
Clearance ofExogenous TGF-Sfrom the Intra-articular Space.
￿
An
aliquot of mI-TGF-01 (50,000 cpm/ng) containing 90,000 cpm
wascombined with 1,ag unlabeledTGF-Oand injected as described
above. At each time point, rats were killed and the entire knee
joints removed andbisected, and associated radioactivity was quan-
titated with a gamma counter. Two rats were used for each time
point, both knees were injected, and, except for certain time points
examined by histological methods (see below), all were counted .
Portions of liver, spleen, kidney were also removed for counting
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to confirm that the TGF-(3 had entered the circulation and was
beingremoved through the expected hepatic clearancepathway de-
scribed by others (25) . At certain time points, intact knee joints
were fixed in 10% neutral buffered formalin, acid decalcified, em-
bedded in paraffin, and sections subjected to an autoradiography
protocol to determine the spatial distribution of '13I-TGF-01 in the
tissue. Exposure timesranged from 3 dfor the earliest time points
post-injection (10 min) to 3 wk for the latest (24 h) .
Kinetics ofPMN Recruitment by TGRa1 In Viva
￿
At the indi-
cated times after intra-articular injection of 1 FAg hrTGF-/31 in sterile
PBS with 0.01% BSA (PBS/BSA), or sterile PBS/BSA in con-
tralateral knees, knee joints were acetone fixed and embedded in
glycol-methacrylate without decalcification . This technique greatly
improves morphological details and allows dual nonspecific esterase
cytochemistry to be performed to identify infiltrating inflamma-
tory cells as either monocytes or PMNs. PMNs are positive for
napthol AS-D chloroacetate ester, staining bright red/purple,
whereas monocytes, positive for a-naphthyl acetate esterase, stain
a diffuse black/brown ; thus, the two cell types are clearly distin-
guishable. Sections were routinely counterstained with0.1% tolu-
idine blue or, after esterase staining, with Mayer's hematoxylin.
Sufficient morphological detail was achieved with these techniques
to permit the direct quantitation of PMNs after esterase cyto-
chemistry by counting cells at x400 in 50 microscopic fields, which
wasperformed for the 1-wg dose . The sections examinedwere chosen
at random from a series representative of a 100-Jtm region taken
from the center of thejoint in the sagittal plane of section . Con-
trol knees injected withPBS were examined by the same method
to determine the number ofPMNs present due to the injection
trauma alone. This number of PMNs, which was always <20%
of thenumber found in theTGF-0-injected knees, was subtracted
in each case to arrive at the data shown. The values reported are
the averages of numbers ofPMNs determined for at least two rats
at each time point. Similar analyses were performed6h post-injection
with 10, 20, 40, 100, 250, and4,000 ng, as well, to assess thedose
responsiveness of PMN recruitment .
Neutrophil Chemotaxis Assay. PMNs were isolated from
heparinized bloodfrom normal humandonors by gravity sedimen-
tation for30 min at room temperature after mixing with an equal
volume of 3% dextran (229,000 mol wt) (Sigma Chemical Co.)
in 0.9% NaCl. Sedimented cells were mixedwith an equal volume
of 0.9% NaCl and centrifuged at 200 g for 10 min at 4°C. The
recovered cell pellet was exposed to 10 ml ofa0.2% NaCl solution
for 20 s to lyse contaminating erythrocytes and then mixed with
10 ml ofa 1.6% NaCl solution to make the mixture isotonic. RPMI
1640 wasadded to the cell suspension, whichwas then centrifuged
as described above, andresuspended at a final concentration of 1.5
x 106 cell/ml in RPMI 1440 .
The cell suspension was added to the upper compartments of
modified blind-well Boyden-type chemotaxis chambers previously
prepared to contain in theirlowercompartmentsRPMI 1640with
andwithout different concentrations ofnatural orrecombinant TGF-
0-1, orFMLP Theupper andlower compartments were separated
by a polycarbonate filter with 2-pm pores (Nucleopore, Pleasanton,
CA). Loaded chambers were incubated for40 min at 37°C. After
incubation, filters were removed from thechambers, stained with
hematoxylin, and mounted on glass slides. Chemotactic activity
was quantitated by counting in 10 oilimmersion fields, at x1,000
magnification, the number ofPMNs that migrated and adhered
to thelower surface of each filter. Sampleswere tested in quadru-
plicate, and results are expressed as the mean or mean ± SEM of
PMNs/OIF of the replicas for each sample tested .
PMA Stimulated Release ofTGROfrom IsolatedPMNs.
￿
Human
Transforming Growth Factor 0 in the Pathogenesis of Arthritidesperipheral bloodPMNs were isolated essentiallyas describedabove
for the chemotaxis assay, except that whole blood was first cen-
trifugedin Ficoll-Hypaque to remove mononuclear cells and platelets
before theDextran sedimentation step.ThePMNs were finally sus-
pended in Hank's salts (calcium- and magnesium-free) at 1-2 x
10' cells/ml . PMA was added to a final concentration of 100
ng/ml, and the cells and controls were incubated for 30 min at
37°C . Cells were then removed by centrifugation in a microfuge
and aliquots of the supernate removed for TGF-0 assay . Aliquots
of the supernates were transiently acidified with HCl for 60 min
at room temperature to activate any latentTGF-0 present and then
neutralized with NaOH before assay. The experiment shown is
representative of three independent experiments with cells from
different donors. Although TGF-ail activity was always detected
in the cell-free supernates, basal rates of secretion (without PMA)
were somewhat variable, presumably due to spontaneous degranu-
lation as a consequence of the conditions required for isolation .
Routinely, cytofuge preparations of the purified PMNs were
Wright's stained; thepredominant cell contaminant was the eosin-
ophil (N5%) with no evidence ofthe presence ofplatelet aggregates
or individual platelets (removed in the Ficoll-Hypaque step). Less
than 1% monocytes/lymphocytes were found in these preparations .
Serumfree Colony Formation Assayfor TGF-(3.
￿
This assay was
performed essentially as previously described (26), except that cell
stocks were maintained on 5% FCSand the concentration ofhuman
highdensity lipoproteinwasreducedfrom 100 to 40 mg/ml . Briefly,
a hyperresponsive clone of a rat kidney fibroblast cell line, NRK-
49F, is used as an indicator cell in a serum-free anchorage-
independent growth assay. On the day of the assay, subconfluent
stock cultures of NRK-49F cells were washed several times with
serum-free basalmedium for 1 h at 37°C to remove residual serum
factors before trypsinization andsuspension in soft-agar to initiate
the assay. High sensitivity of TGF-0 detection is achieved in this
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Figure 1.
￿
Kinetics ofTGF-131 in the rat knee joint space. 1251-hrTGF-
01(90,000cpmwith 1wg unlabeled hrTGF-S1) was injected into the intra-
articular space.At the times indicated, animals were killed, the kneejoints
removed, bisected transversely with care to retain any fluid present, and
each half was placed in a tube for a determination of the total amount
of 1251-hrTGF-01 present in the tissue. Each point represents the average
value obtained from at least three knee joints from two different rats.
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assay (levels >10 pg/ml) with a serum-free medium comprised in
part of insulin, transferrin, human high density lipoprotein,
epidermal growth factor, and retinoic acid. Antibody neutraliza-
tion of the TGF-0 bioactivity was used for confirmation.
Extraction ofTotal TGF/0from PMNs and Analysis by ELISA .
PMNs wereprepared exactly as described aboveand then subjected
to an acid-ethanol extraction procedure originally described for use
with platelets (27, 28) . The final precipitate containing theTGF-0
was dissolved into 1M acetic acid, dialysed against 10 mM acetic
acid, and aliquots were analyzed in triplicate byELISAusing a re-
cently described protocol and TGF/01-specific mAbs (29) .
In Vivo Synovial Cell PHJ Thymidine Labeling.
￿
Adult OuJ mice
were subjected to the hrTGF-01 intra-articular injection protocol ;
a 31-gauge needle was used to minimize injection trauma. After
70 h, 60 Al of [3H] thymidine (2.0 Ci/mmol) was introduced by
intraperitoneal injection. At 72 h post-injection, mice were killed,
andthe knee joints anda small sample of small intestine (to serve
as a control to confirm that labeling ofproliferating cells was achieved
with each animal) were fixed in Camoy's solution overnight, de-
hydrated, andembeddedin glycol methacrylate. Sections weredipped
inF.5 emulsion (Ilford Scientific Products, Mobberly Cheshire, UK),
exposed for 3 wk, developed in Kodak D-19 developer, counter-
stained, andexamined by light microscopy . Labeling indexandmi-
totic indexwere determined by counting the totalnumber of nuclei
ofresident tissue cells, thenumber oflabeled nuclei,andthenumber
ofmitotic figures observed in 15 microscopic fields takenfrom the
synovial membrane area and underlying tissue.
Results
ClearanceofInfectedTGF ,0from the Tissue
￿
First, the clear-
ance time ofTGF-/31 injected into thejoint space wasdeter-
mined . 1 hg of unlabeled TGF-01 was added to 3-5 ng of
1251TGF-01 before injection . As shown in Fig. 1, the in-
jected 1251-TGF-01 was cleared from the joint space with a
half-life of ti1 h. As expected from previous studies (25),
after -30 min, radioactivity was detectable in the liver, and
to a lesser extent in the kidney and spleen . The amount of
1251 increased in these organs as a function of time for sev-
eral hours (data not shown) . The rapid clearance of TGF-0
maybe duein part to increased vascular permeability reflected
by plasma exudate formation in thejoint space, observed in
histological studies performed simultaneously (see below) .
In spite of the rapid clearance of most of the injected TGF-
01, significant amounts ofTGF-S1 mayremain in the tissue
many hours after its injection.
To determine the spatial distribution of the injected 1251-
TGF-(31 at selected times post-injection, kneejoints were fixed
in formalin, processed for paraffin embedding, and replicate
tissue sections were subjected to autoradiographic analysis .
Since 1 Ag of unlabeled TGF-01 was added to the 1251-TGF-
01 before injection to duplicate the conditions used in the
rest of the study, specific binding to cell receptors was ob-
scured by "nonspecific" associations with othercomponents
of the tissue. At the earliest times examined (10-30 min),
silver grains were primarily associated with the innermost
surfaces of the synovial membrane andarticular cartilage. At
later times (4-24 h), the silver grains were preferentially dis-
tributed within the cartilage matrix and penetrated further
towards the subchondral bone with time, probably due toelectrostatic interactions between TGF-01 (pI = 9.8) (23,
30) and the overall negatively charged cartilage matrix (data
not shown) .
Neutrophil Recruitment Induced by TGR0 Intra-articular In-
jection .
￿
Within 2 h after injection, two striking morpho-
Figure 2 .
￿
Influx ofPMNs into vascular elements and the synovial mem-
brane after intra-articular injection ofhfIGF-#1 . 6 h after injection of 1 ILg
of hrTGF-#1,joints were processedfor glycol-methacrylate embedding and
histologial analysis. Sections (3 um) were counter stained with toludine
blue. (A) PMNs in a large vascular element in the synovial fat pad ; (B)
microvascular elements (arrows) in synovial fat pad with PMNs emigrating
into avascular space ; (C) synovial membrane with PMNs (arrow heads)
traversing into the joint space (original magnification, -400) .
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logic changes were apparent in the synovial tissues. These
were the infiltration ofPMNs into the tissue and the appear-
ance of plasma exudate on the surfaces of the synovialmem-
brane and articular cartilage, as well as within thejoint space.
As shown in Fig . 2 A and B, the magnitude of the PMN
immigration was very dramatic at its peak with large numbers
ofPMNs observed in most vascular elements . Many PMNs
were present in interstitial regions in the infrapatellar fat pad
subjacent to the synovial membrane and were also observed
migrating into and through the synovial membrane itself (Fig .
2 C) . An exuberant plasma exudate infiltrated by PMNs
formed within thejoint space within 4-6 h, and at later times
(after 8 h), monocytes were present as well (data not shown) .
PMNs and monocytes embedded in the material were pre-
sumably engaged in degradation of the fibrin-containing ex-
udate (31) . It is not yet clearwhat mediates the vascular per-
meability changes responsible for the exudate formation ;
TGF-(3 effects on endothelial cells consistent with induction
ofvascular permeability changes have not yet been reported .
The large number ofPMNs crossing the endothelial barrier
may contribute to the permeability changes through release
of other mediators. The amount of inflammation induced
by injection trauma in the saline-injected control knees was
much less than that seen with theTGF-O injection, although
occasionally, bleeding into the joint occurred as evidenced
by erythrocytes present in the joint space.
The responses described above were not consistently ob-
served at lower doses ofTGF/a tested (10-100 ng), and were
observed to be significantly reduced at 250 ng . The neutro-
phil recruitment observed with a 4-dug dose was not sig-
nificantly different from that seen with the 1-Ag dose. It is
not clear why the PMN recruitment response appears to re-
quire a threshold dose of ti1 Wg of TGF/0, although the ca-
pacity of tissue components to sequester TGF-a, especially
the cartilage matrix, may be responsible.
Figure 3 .
￿
Kinetics and quanti-
tation ofneutrophil influxinto the
synovial membrane after hfrGF-
(31 injection. At the time indicated
after injection of 1 ug of hfIGF-
01, or PBS into the contralateral
knees as controls, kneejoints were
acetone fixed and embedded in
glycol-methacrylate medium . Sec-
tions were subjected to an esterase
cytochanial stain (naphthol AS-D
chloroacetate esterase) to distin-
guish PMNs from monocytes.
PMNs in the area ofthe synovial
membrane werecounted in 50 mi-
croscopic fields on three to five
3-Am sectionsin the sagittal plane,
randomly selectedfrom the center
ofthekneejoints . Two rats were used for each time point, and the number
ofPMNs/10 fields in the PBS-injected knees was subtracted to obtain the
values shown. PMNs present in the exudate in thejoint space were not
counted unless directly adherent to the synovial membrane.Kinetics ofPMN Recruitment into Synovial Tissue.
￿
Tissue
sections prepared at various times after TGF-/31 or saline intra-
articular injections were subjected to a nonspecific esterase
cytochemistry procedure and examined. Most infiltrating cells
present at early times were PMNs with a gradual enrichment
in monocytes seen later (8-12 h) . To quantitate this response,
PMNs were counted in 50 random microscopic fields (x400)
at 2, 4, 6, 8, and 12 h after hrTGF-(31 injection and corrected
for thePMN recruitment that resulted from injection ofPBS
alone . Only PMNs present in the synovial membrane were
counted ; each field counted included the intimal lining layer
of synoviocytes, similar to the field shown in Fig. 2 C . Al-
though some microvascular elements were included in the
count, most cells that were counted were observed traversing
the synovial membrane interstitium . PMNs were also abun-
dant throughout the infrapatellar fat pad, but these were not
included in this quantitation . As seen in Fig. 3, the peak of
PMN influx occurred ti6 h post-injection . Monocytes began
to appear in the tissue NS h post-injection, and at 12 h post-
injection, more than halfof the infiltrating cells stained posi-
tively for the monocyte marker, a-Napthyl acetate esterase
(data not shown) .
Ultrastrutural Characterization ofthe Synovial Membrane The
studies described above indicated that monocytic cells arrived
later and persisted longer than PMNs in the tissue. Many
appeared to remain present 4 d post-injection, primarily at
the surface of the synovial membrane . At this time, the sur-
face of the synovium was enriched with cells withmembrane
projections that could be resolved with the light microscope
in semithin sections (data not shown) . When examined by
EM, these cells were found to be engaged in both pinocytic
(data not shown) and phagocytic activity, as illustrated in
Fig. 4. The tightly interconnected nature of the cells nor-
mally associated with the surface of the synovial membrane
was less apparent (32) ; intimal lining cells were loosely as-
sociated with the synovial surface . Many such cells had fea-
Figure 4 .
￿
Ultra-structural appearance of the synovial membrane surface 4 d after intra-articular injection of TGF-01 . Animals were killed at the
time indicated,joint spaces were injectedwith4% glutaraldehyde fixative in phosphate buffer, the infrapatellar fat pad was dissected, and small specimens
were fixed an additional 6 h. The specimens were osmicated and embedded in EPON resin for ultrastructural analysis. Cells with the morphological
appearance of monocytes and bearing numerous surface extensions were often observed at the surface, and appeared to be actively engaged in pinocytosis
and phagocytosis. The majority of intracellular inclusions were empty pinocytic vacuoles (data not shown), although some of the intracellular vesicles
contained electron-dense material (arrows), as shown in theinset, presumably fibrin and otherexudate components. Originalmagnification, 6,000 ; inset, 30,000 .
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Direct chemotactic effects of TGF-fi on human peripheral
blood PMNs and comparison with FMLP . Isolated human PMNs were
subjected to a chemotaxis assay in Boyden chambers exactly as described
in Materials and Methods . Quantitation was performed by counting cells
that had migrated through a 2-Am pore size Nucleopore filter in response
to the factor present on the other side of the membrane at the indicated
concentrations. The data arereported as number ofcells per 10 oil immer-
sion fields (x1,000). (A) TGF-/91; (B) FMLP.
Table 1 .
￿
Elects ofVarying TGF,B Concentrations on PMN Migration
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tures indicative of monocytes with cytoplasmic extensions
and filapodia, a typical crescent-shaped nucleus and cytoplasmic
heterophagic vacuoles/lysosomes, as shown in Fig. 4 (arrows
and inset) . The majority of the cells on the synovial mem-
brane surface also displayed highly convoluted membrane
projections and "empty" vacuoles, reflecting pinocytic activity
of the cells.A striking similarity was noted between the ul-
trastructural appearance ofcells populating the synovialmem-
brane 4 d after TGF-a1 injection to those reported in this
location during the early stages of type II collagen-induced
arthritis (32) .
Direct chemotactic Effects of7GF/,B on IsolatedPMNs .
￿
Since
the data obtained in vivo indicated that TGF-01 rapidly
recruited neutrophils to the site of injection, it was of in-
terest to determine whether TGF-S had direct chemotactic
effects on PMNs. The ability of native and recombinant
TGF-01 to induce PMN chemotaxis was assessed by the
Boyden chamber technique. Both hrTGF-191 and natural por-
cineTGF-01 stimulated migration of peripheral bloodPMNs
in a dose-dependent manner, as didFMLP (Fig. 5) . The dose-
response curves for natural TGF-01 (Fig. 5A) and rhTGF-131
(data not shown) were essentially bell shaped, as has been
shown for monocytes and fibroblasts, other cell types for which
TGF-S is known to be chemotactic (10, 13) . The ability of
the purified porcine TGF-191 to induce a chemotactic response
to PMNs was blocked with neutralizing antibodies (data not
shown). A Zigmond-Hirsch checkerboard analysis revealed
that TGF-(31 affected the migration of PMNs only when
present in higher concentration in the lower compartment
of the chemotaxis chamber (Table 1), showing that it induces
chemotactic migration and not simply chemokinesis (33) .
It was ofinterest to assess and compare the magnitude of
PMN migration induced byTGF/01 and a standard chemoat-
tractant, FMLP Therefore, dose-response curves for both
chemoattractants were determined in the same chemotaxis
assay. FMLP induced maximal migration at a concentration
of 5-10 nM, which was of a lesser magnitude than that ob-
served with hrTGF/01(Fig. 5). Similar results were obtained
Different concentrations of porcine TGF-S were added to the upper and lower compartments of chemotaxis chambers, and the number of neutrophils
migrating to the lower surface of each filter was quantitated . The values represent the mean t SEM of triplicate determinations .
TGF-/3 concentration
in upper compartment 7.80
PMNs per 10 OIF at
3.40
TGF-(3 concentration (fg/ml
1 .70
in lower compartment)
0.85 0
.fglml
7.80 50 ± 12 30 ± 6 33±4 33±6 37±6
3.40 42±2 34±4 31±4 14±5 29 t6
1 .70 81±9 65±8 65±9 44±10 38±11
0.85 92 ± 9 87 ± 13 54±4 35±5 34±5
0 26 ± 3 168 ± 17 113 t7 85±4 66±12when the experiment was repeated . These results indicate that
not only is TGF-}81 >100,000 times morepotent than FMLP
at inducing PMN chemotaxis, but that the magnitude of the
chemotactic response is greater than that observed withFMLP,
in the chemotaxis assay used in this study.
Release ofTGROfrom PMNs by Degranulation.
￿
It is pos-
sible that PMNs may be a significant source of TGF-O in
vivo (34, 35). To examine the question of whether or not
TGF-R could be released from peripheralbloodPMNs in con-
junction with degranulation in vitro, we chose to use a well-
characterized specific granule secretagogue, PMA (36, 37) .
TGF-6 activity was assayed by a traditionalbioassay, anchorage
independent growth ofNRK-49 cells (26) .As shown in Fig.
6 B), TGF-[3 activity was released from freshly isolatedPMNs
incubated with 100 ng/ml PMA at 37°C for 30 min . There
was little detectable activity released from unstimulatedPMNs.
Immunological neutralization ofthe activity secretedbyPMA
stimulatedPMNs, with anIgG fraction of an antiserum pre-
pared against native TGF-/3, confirmed that the colony for-
mation was due to TGF-,8 (Fig. 6 B) .
An additional immunologic method confirmed the iden-
tity of the TGF-01 present and was used to determine the
quantity ofTGF-01 contained in this novel storage site. Aliquots
of acid/ethanol extracts of human peripheral blood PMNs
were analyzedby a recently developed TGF-01-specificELISA
that uses twomAbs that recognize TGF-S1 . The mean level
of TGF-01 determined by the extraction of three prepara-
tions of-109 PMNs was found to be 355 ng/109 cells (SD
= 44.4 ng) . In addition, since the conditions chosen for the
PMN-induced secretion ofTGF-O from PMNs described in
the above experiments were suboptimal for degranulation,
PMNs were also stimulated with PMA in the presence of
5 Wg/mI cytochalasin B to optimize degranulation (38) . In
this case, PMNs released 44% of their total stored TGF-01
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Figure 6. PMA-induced release of
TGF-,6 from peripheral blood PMNs
and antibody neutralization. Isolated
PMNs wereincubated for 30 minwith
100 ng/ml PMA in Hank's medium,
and cell-free supernates were analyzed
for total TGF-,B in a soft-agar colony
formation assay. Response to 10% FCS
represents colony formation by-85%
ofthe cells initially plated (-200 colo-
nies per four microscopic fields). (A)
The dose response to the addition of
0, 2, 8, and 32 pg/ml hrTGF-01 ; 32
Pg/mI hrTGF-01 plus 25 Pg anti-'PGF-0
IgG (+Ab) ; 32 pg/ml hf1GF-Sl plus
25 1Ag normal rabbit serum IgG
(+NRS); 10% FCS. (B) The response
to the addition of 100-P1 aliquots of
cell-free supernates from PMA-treated
PMNs either alone (PMA); with 25 pg
antiTGF-S IgG, (PMA+Ab) ; or with
25 1+g normal rabbit serum IgG,
(PMA+NRS) . Also shown is addition
of 100 ul of supernatant from PMNs
incubated without PMA, (-PMA) .
(measured by ELISA after in vitro acid activation of cell-free
supernates) .
TGRO InducedProliferutive Effects in Synovial Tissue
￿
In other
studies, mitotic figures were observed in synovial tissue 72 h
after initiating daily injections of TGF-01 (39) . Therefore,
we first compared the effects ofour single injection protocol
to those produced by multiple injections of TGF-al,
monitoring the number and location ofmitotic figures 72 h
post-injection. Rats were given either a single injection of
1 Ag TGF-01, or daily injections of 1 lAg TGF-01 into the
same kneejoint . With either protocol, mitotic figures were
occasionally observed 72 h post-injection, with no obvious
differences detected in the frequency or location ofthe dividing
cells (data not shown) . In both cases, mitotic figures were
seen in various regions of the synovial membrane, including
cells close to thejunction ofthe synovium with the articular
cartilage, as illustrated in Fig . 7A . With the administration
ofa single injection ofTGF-/31, however, there were markedly
fewer inflammatory cells present in the tissue at 72 h com-
pared with thenumber observed with the multiple injection
protocol .
To determine the full extent of the proliferative response
in the tissue triggered by TGF-01 injection, intra-articular
injection experiments were repeated in mice that also received
a 2-h pulse of [3H]thymidine 70-72 h after the single TGF-
01 injection. The proliferativeresponse was found to bemuch
more widespread when analyzed by this method . As shown
in Fig. 7 B, resident synovial membrane cells and another
cell type of uncertain identity scattered throughout the sub-
jacent synovial areolar tissue were labeled with [3H]thymi-
dine. Another interesting aspect revealed by [3H]thymidine
labeling was that many tendon cells also proliferated 72 h
after TGF-01 injection ; this effect was observed to occur both
near and quite far from the actual site of injection (data notshown) . The labeling index was determined to be from 5
to 15% for tendon cells and from 9 to 11% for cells in the
vicinity ofthe synovial membrane, whereas the mitotic index
(mitotic figures) was from 0.1 to 0.5% for synovial mem-
brane cells . There was no evidence of proliferation of en-
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Figure 7 .
￿
Proliferative response of synovial cells 72 h
after TGF-01 intra-articular injection in the kneejoint
space. Rats (A) or mice (B) received 1 Ftg TGF-01 by
intra-articular injection or saline control of equal
volume in the contralateralkneejoint space. After 70 h,
the mice received 60 uCi [3H]thymidine injected in-
traperitoneally. After death the kneejoints werefixed
and embedded in glycol-methacrylate medium, and
3-,um sections were subjected to autoradiography with
F.5 emulsion (Ilford) and developed in Kodak D-19 .
Exposure time was 3 wk . (A) Mitotic figure (arrow)
observed in the vicinity of the cartilage/synoviumjunc-
tion in the rat knee; (B) mitoticfigure (unlabeled) and
examples of labeled cells (up arrows) in more fibrous
region of the synovium of the mouse (original
magnification, 400) .
dothelial, smooth muscle, or striated muscle cells seen at this
time point after TGF-/31 injection .
Control (PBS-injected) contralateral knees that displayed
no histological signs of injection trauma showed no labeling
of cells, nor were mitotic figures ever seen . The basal rateof synovial cell proliferation in mice that did not receive intra-
articular injections of any type was also undetectable by
[3H]thymidine pulse labeling . Interestingly, in one control
knee in which signs of injection trauma were apparent (RBC,
fibrin, inflammatory cells), there also was a proliferative re-
sponse, suggesting that the same mediators are present after
traumatic tissue injury as are triggered by TGF-01 injection .
Thus, the increased number ofcells observed in the synovial
membrane 4-6 d post-injection (40) were in part due to the
proliferation of both resident synovial cells and another
unidentified cell type located somewhat remotely from the
synovial membrane surface.
Discussion
We have observed and characterized a very rapid and dra-
matic PMN recruitment mediated by TGF-S1 in vivo that
precedes, and is therefore likely to play a central role in, TGF-
01-induced synovial hyperplasia. The precise mechanism(s)
by which TGF-# recruits PMNs to synovial tissue in vivo
is not entirely clear ; however, the ability ofTGF-S1 to stimu-
late a chemotactic response by peripheralbloodPMNs in vitro
identifies one possible component . The remarkable potency
of TGF-01 in eliciting this response (>100,000 times more
potent than FMLP) must qualify TGF-/31 as the most potent
chemotactic agent for PMNs known to date. Although the
in vivo PMN recruitment we observed was rapid and exten-
sive, little data from other experimental systems help in un-
derstanding the mechanics of this response. In fact, in vitro
studies with culturedhuman umbilical cord endothelial cells
and isolated peripheral bloodPMNs would suggest thatTGF-0
would be inhibitory to PMN-endothelial cell interactions,
through its ability to decrease PMN adhesiveness to endothelial
cells (albeit only modestly) (41) . It may be important to note,
however, that this effect was observed after 6-24 h of ex-
posure of endothelial cells to TGF-S ; it is possible that this
phenomenon contributes to attentuation of the PMN recruit-
ment at later times after TGF-a injection. It is not known
whether TGF-a can induce expression of other neutrophil
chemotactic factors, such as IIT8 . The involvement of resi-
dent mast cells in the tissue remains a possibility (42), al-
though TGF-0 does not stimulate release of mediators from
bone marrow-derived mast cells (43) .
TGF-a receptors on isolated peripheral blood PMNs have
not yet been characterized in detail . In preliminary experi-
ments, we have observed specific binding of 1251-TGF-a1 to
N8,000 receptors/cell . The TGF-/31 binding characteristics
displayed by PMN receptors were similar to that seen with
many other cell types; cell surface binding and saturation oc-
curred in the same concentration range as observed for TGF-a
binding to most other cell types, from -0.1 to 10.0 ng/ml
(Fava, R.A ., unpublished results) . This concentration range
is several orders ofmagnitude greater than the doses at which
the chemotactic response was observed, and it therefore is
unclear whether the chemotactic response is mediated through
the types of receptors usually described for TGF-(31 binding
(44-46) . This difference in receptor-binding characteristics
and the dose required for a chemotactic response is not un-
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precedented ; others have reported similar discrepancies be-
tween the very low concentrations ofTGF-(3 required to elicit
a chemotactic response by monocytes (peak activity at 0.02
pM) and an apparent affinity of cell surface receptors that
require 40 pM TGF-0 for saturation (13) . Unfortunately, it
is impossible to radioactively label TGF-a1 to a sufficiently
high specific activity to perform the equilibrium-binding ex-
periments necessary to demonstrate the existence of receptors
with the affinity constants expected for a biological response
in the fg/milliliter range .
In other studies, immunoreactivity for TGF/f3 in inflam-
matory neutrophils has been observed (35), and it also has
been shown that human peripheral blood PMNs contain
mRNA for TGF-S, and that the protein is detected in cul-
ture medium afterPMNs are incubated in culture dishes for
24 h (34) . These data suggest that PMNs have the capacity
to phagocytose, synthesize, and/or secrete TGF-S . One pos-
sibility is that the TGF-a found in the culture medium had
been previously synthesized and may have been released from
storage granules duringPMN degranulation that occurs during
attachment and contact with the culture surface. Recently,
we have obtained evidence by immuno-localization techniques
at the ultrastructural level that TGF-/3 is in fact detectable
within granules of neutrophilic myelocytes in bone marrow,
the precursors of mature peripheral blood PMNs (47; and
unpublished results) . Our ability to demonstrate that TGF-/3
was secreted from PMNs stimulated with a known specific
granule secretagogue PMA supports the notion that PMNs
may be an important source of stored TGF-(3 in vivo. Our
quantitation of acid/ethanol extracts of peripheral bloodPMNs
reveals that PMNs contain -1/20 the amount of TGF-(3
stored in platelets, if compared on a wet weight basis (48).
That TGF-(3 may be delivered via this novel mechanism
whenever there exists a signal to triggerPMN degranulation
in vivo has broad implications in wound healing and chronic
immune-driven inflammation . The identification of PMNs
as a potential source of presynthesized TGF-0 in vivo may
also explain a recently reported paradox concerning the high
levels ofTGF-0 observed in synovial effusions, even though
very little mRNA for TGF-(3 has been detected by in situ
hybridization of isolated synovial tissue cells in vitro (49) .
Recently, Allen et al . (39) reported that multiple intra-
articular injections of 1 ttg TGF-/31, at 24-h intervals, had
the capacity to induce a synovial hyperplasia similar to that
described in the present study. The evidence for cell prolifer-
ation consisted primarily of mitotic figures that were observed
72 h after the initiation of the TGF-/31 injections. We also
observed a round of replication at this time, however, with
the important difference that only a single injection ofTGF-
(31 was used in our studies . With a single injection ofTGF-
01, recruitment of inflammatory cells occurred as a transient
phenomenon with relatively few monocytic cells observed
in the synovial tissue at the time of cell division. This situa-
tion differs significantly from the results of Allen et al . (39),
who have proposed that contact, or at least close proximity
of fibroblastic cells with monocytes, mediates the TGF-01-
induced proliferation of synovial cells, possibly through the
induction and secretion ofmacrophage-derived mediators suchas IIA. We attribute the paucity of monocytes observed in
the subsynovial tissue at the time of cell proliferation in our
study to the single-injection protocol thatwe used . We pro-
pose that daily injections ofTGF-a leads to a superimposi-
tion of monocyte recruitment over the proliferative response
and that this repeated monocyte recruitment is not required
for the TGF-0 induction of synovial cell proliferation seen
72 h post-injection . With regard to the importance of ID1
production by monocytes in the proliferative response, it is
important to note that although TGF-0 increases levels of
mRNA for IIA in monocytes (13, 49a), themRNAmay not
be translated, as little 114 bioactivity is secreted byTGF-0-
stimulated PBMC (49a) . Moreover, TGF-0 has been shown
to significantly reduce the levels ofIIAR in some cell types
(50) . Thus, the importance of IIrl as a secondary mediator
in TGF-/3-induced synovial cell proliferation remains to be
proven .
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